Literature DB >> 29134301

Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium.

Junyan Zhu1,2, Doris Mayr3, Christina Kuhn1, Sven Mahner1, Udo Jeschke4, Viktoria von Schönfeldt5.   

Abstract

Prostaglandin E2 (PGE2) is well described to be associated with both endometrial functions and disorders. The primary aim of this study was to explore the underlying mechanisms that affect the growth and function of endometrial epithelium and stroma by assessing the staining intensity of PGE2 receptors (EP) in healthy endometrium across the menstrual cycle and in pathological endometrium, such as ovarian endometriosis and endometrial cancer. We retrospectively analyzed the EPs staining intensity in human nonpregnant endometrium throughout the menstrual cycle by immunohistochemistry and further focused on EP1 (n = 42). The variation of EP1 was compared among healthy endometrium, ovarian endometriosis (n = 14), and endometrial cancer (n = 140) crosswise. EP1 presented cyclical changes with increased intensity in both epithelium and stroma during the proliferative phase. EP1 staining in the epithelium was increased in endometriotic tissue compared to healthy endometrium and tumor tissue, while in the stroma, the staining in the tumor was lower than that in both normal tissue and endometriosis. No significant differences in EP1 intensity were detected for histological, stage, grading, metastatic and recurrent subtypes in endometrial cancer. EP1 was also correlated with neither progression-free survival nor overall survival of patients with cancer. EP1 staining in progesterone receptor B (PRB)-positive tumor was stronger compared to PRB-negative tumor. EP1 may play a role in human endometrial physiology and pathology. Further studies on the effect of EP1 on human endometrium are needed.

Entities:  

Keywords:  EP1; Endometrial cancer; Endometriosis; Endometrium; Progesterone receptor B

Mesh:

Substances:

Year:  2017        PMID: 29134301     DOI: 10.1007/s00418-017-1616-y

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  46 in total

Review 1.  Leukocytes and resident blood cells in endometrium.

Authors:  J N Bulmer; M Longfellow; A Ritson
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Early menstrual characteristics associated with subsequent diagnosis of endometriosis.

Authors:  Susan A Treloar; Tanya A Bell; Christina M Nagle; David M Purdie; Adèle C Green
Journal:  Am J Obstet Gynecol       Date:  2009-12-22       Impact factor: 8.661

3.  Prostaglandin E2 induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes.

Authors:  Silvana Caristi; Giovanna Piraino; Maria Cucinotta; Andrea Valenti; Saverio Loddo; Diana Teti
Journal:  J Biol Chem       Date:  2005-01-19       Impact factor: 5.157

4.  Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities.

Authors:  Xinrong Ma; Namita Kundu; Olga B Ioffe; Olga Goloubeva; Raymond Konger; Claudia Baquet; Phyllis Gimotty; Jocelyn Reader; Amy M Fulton
Journal:  Mol Cancer Res       Date:  2010-09-21       Impact factor: 5.852

Review 5.  Abnormal peritoneal regulation of chemokine activation-The role of IL-8 in pathogenesis of endometriosis.

Authors:  Justyna Sikora; Marta Smycz-Kubańska; Aleksandra Mielczarek-Palacz; Zdzisława Kondera-Anasz
Journal:  Am J Reprod Immunol       Date:  2017-01-25       Impact factor: 3.886

6.  Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.

Authors:  Jeanette A Richards; Robert W Brueggemeier
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 7.  TH1/TH2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the TH1/TH2 paradigm.

Authors:  Gérard Chaouat; Natalie Ledée-Bataille; Sylvie Dubanchet; Sandrine Zourbas; Olivier Sandra; Jacques Martal
Journal:  Int Arch Allergy Immunol       Date:  2004-05-17       Impact factor: 2.749

8.  Prostanoid receptor EP1 expression in breast cancer.

Authors:  Mangesh A Thorat; Akira Morimiya; Sanjana Mehrotra; Raymond Konger; Sunil S Badve
Journal:  Mod Pathol       Date:  2007-09-28       Impact factor: 7.842

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 10.  Menstrual physiology: implications for endometrial pathology and beyond.

Authors:  Jacqueline A Maybin; Hilary O D Critchley
Journal:  Hum Reprod Update       Date:  2015-08-07       Impact factor: 15.610

View more
  5 in total

1.  In focus in HCB.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2018-01-15       Impact factor: 4.304

2.  HORMONAL THERAPY IN WOMEN OF REPRODUCTIVE AGE WITH ENDOMETRIOSIS: AN UPDATE.

Authors:  A A Gheorghisan-Galateanu; M L Gheorghiu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

3.  Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses.

Authors:  Yao Ye; Aurelia Vattai; Nina Ditsch; Christina Kuhn; Martina Rahmeh; Sven Mahner; Myriam Ripphahn; Roland Immler; Markus Sperandio; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Endocr Connect       Date:  2018-04-26       Impact factor: 3.335

Review 4.  COX-2-PGE2-EPs in gynecological cancers.

Authors:  Yao Ye; Xipeng Wang; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Arch Gynecol Obstet       Date:  2020-05-03       Impact factor: 2.344

5.  Novel SLCO2A1 mutations cause gender differentiated pachydermoperiostosis.

Authors:  Lijuan Yuan; Xihui Chen; Ziyu Liu; Dan Wu; Jianguo Lu; Guoqiang Bao; Sijia Zhang; lIfeng Wang; Yuanming Wu
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.